No registrations found.
ID
Source
Brief title
Health condition
We will include subjects from the Amsterdam HELIUS study (n=6000) and include only those with 10% lowest and 10% highest fecal butyryl-coenzyme A transferase enzyme (based on previously obtained results of 16S analysis and cross-validated by qPCR butyryl CoA transferase) will be approached for this study.
Sponsors and support
Intervention
Outcome measures
Primary outcome
- differences in Postprandial plasma acetate levels after a SMMT
- differences in Baseline Intestinal microbiota composition (morning stool samples)
- differences in baseline Faecal acetate levels
Secondary outcome
- CNS (fMRI) responses to food pictures (BOLD) signal, i.e. in CNS activation in predefined regions (insula, striatum, amygdala, OFC, PFC, hippocampus and hypothalamus) in response to viewing food pictures or consuming actual food
- Insulin sensitivity measured as Matsuda’s insulin sensitivity index during the standardized mixed meal test
- Insuline secretion measured as c-peptide response during the standardized mixed meal test
- Energy metabolism, measured by resting energy expenditure (REE)
- Baseline physical activity energy expenditure (PAEE)
- Dietary intake (https://mijn.voedingscentrum.nl/nl/eetmeter), weight and body
composition (Body Impedance Analysis, BIA).
- Subjective appetite sensations and eating behavior (VAS questionnaires)
Background summary
We designed a comparative study to investigate whether a high intestinal acetate production is associated with altered acetate production and whether this affects insulin sensitivity and secretion as well as with neural responses to virtual and actual food stimuli (fMRI).
Study objective
In this study we aim to investigate whether intestinal acetate production by gutmicrobiota is related to (postprandial) plasma acetate levels, insulin secretion/sensitivity and the CNS regulation of food intake (fMRI).
Study design
1 day
Intervention
(high fiber) containing standardized mixed meal test
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
Inclusion criteria
- Male or female
- Stable bodyweight (<5% reported weight change during the previous 3 months)
- Age 18-65 years
- Caucasian (i.e.: Dutch or Turkish nationality)
- Able and willing to give informed consent
Exclusion criteria
- Use of corticosteroids, antibiotics and other immunomodulating medication in last 3 months
- XTC, amphetamine, nicotine or cocaine abuse, based on the 20 item drug abuse screening test (DAST-20)
- Alcohol abuse (> 3 units per day)
- Contraindication for MRI (neurological illness , malignancy, history of major heart
disease, history of major renal disease, pregnancy or breast feeding, pacemaker and
metals contraindicated for MRI present in the body)
- Expected prolonged compromised immunity (due to recent cytotoxic chemotherapy or
- HIV infection with a CD4 count <240)
- Presence of inflammatory bowel disease (IBD)2
- Inability to understand the study protocol, give informed consent or participate
adequately in study protocol
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7131 |
| NTR-old | NTR7328 |
| Other | : METC 2018_053 |